Fermenta bio expected to report revenue growth of 4.6% YoY to INR 941mn, despite of continued traction in the Human VD3 business (80% of overall VD3 sales H1FY22) due to planed shutdown for capacity expansion. However, owing to a high base, the EBITDA margin can contract by 887bps to...